44 results about "Synthetic Immunogens" patented technology

The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope.

A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDRl, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

The present invention relates to synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid β peptides and amyloid deposits.

The invention relates to pyrethroid hapten design based on a computer molecular simulation technique and an application, which belongs to the technical field of pyrethroid pesticide detection. Six kinds of available hapten are designed by using the pyrethroid hapten design. Gaussian software is utilized to calculate charge distribution of the hapten and a target object, and Discovery Studio 2.5 software is utilized to establish spatial conformation of the hapten and the target object. By comparison, the hapten with the highest degree of structure similarity is selected as immune hapten (hapten 1), the hapten is predicted to generate a good immune effect, and the hapten with higher structure difference is selected as coated hapten (hapten 5). The computer molecular simulation software is successfully used by the method to design the hapten of a pyrethroid pesticide; a mass selection antibody which is used for identifying the pyrethroid pesticide is prepared through synthesis of immunogen and immunity, serum screening, fusion, screening and acrylics; the method is proven to have strong predictive ability, and time and funds are saved; and a new method is provided for later analyzing and researching immunology.

The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X₁=a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X₂=a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.

The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.

The invention discloses polypeptide GPR5 and application thereof to promoting of hepatocyte proliferation and inhibiting of hepatocyte apoptosis. The invention discloses polypeptide and application thereof to promoting of hepatocyte proliferation and/or inhibiting of hepatocyte apoptosis. According to the polypeptide capable of promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis, compared with an amino acid sequence shown in SEQ ID NO:1, the amino acid sequence of the polypeptide has 3/5 or above sequence consistency, the polypeptide length is 5 amino acids, the polypeptide has the advantages of being small in molecular weight, easy to synthesize, low in immunogenicity and the like, and therefore the polypeptide has broad application prospects in treatment of hepatopathy.

The invention discloses an application of FGF-2 derived polypeptide to preparation of medicines for promoting cartilage repairing and/or treating degenerative arthritis. The FGF-2 derived polypeptideis polypeptide as shown in SEQID NO:1 or polypeptide as shown in SEQID NO:2. Peptide PDG6 and KED7 are from FGF-2, cartilage can be notably promoted to regenerate, and the FGF-2 derived polypeptide has favorable treatment effects on degenerative arthritis, besides, is easy to synthetize and low in immunogenicity, and has wide application prospects in treatment of cartilage injury and degenerativearthritis.

The invention belongs to the field of biological medicines, and particularly relates to an IKK beta-targeted short peptide and application thereof in inflammatory diseases. In order to provide a moreeffective treatment means for inhibiting inflammatory reaction, the invention provides the IKK beta-targeted short peptide. The short peptide comprises an N-terminal amino acid 46-60 region derived from I kappa B kinase binding protein IKIP, and the N terminal of the short peptide is fused with a cell-penetrating peptide and has a polypeptide marker. The short peptide can target IKK beta and inhibit combination of IKK beta and IKK gamma, thus, formation of an IKK complex is inhibited, expression of inflammatory cytokines TNF-alpha and IL-6 is reduced, and inflammatory reaction is inhibited. Ananimal model shows that the short peptide can effectively treat arthritis and inflammatory enteritis. Compared with full-length proteins, the short peptide has the advantages of small molecular weight, easiness in synthesis, weak immunogenicity and relatively weak side effects; and the cell-penetrating peptide has better absorption, and the polypeptide marker is easy to track and observe, and thus, a reference is provided for clinically treating the inflammatory diseases.

Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed.

The invention discloses application of an MEPE-derived polypeptide in preparing a medicine for treating pancreatitis and a medicine containing the MEPE-derived polypeptide. The MEPE-derived polypeptide is: a) a polypeptide represented by SEQ ID NO:1; or b) a polypeptide composed of amino acids at positions 5-19 in the amino acid sequence of the polypeptide represented by SEQ ID NO:1; or c) a cyclic peptide obtained by cyclization by adding Cys respectively to the N-terminal and C-terminal of the polypeptide composed of the amino acids at positions 5-19 in the amino acid sequence of the polypeptide represented by SEQ ID NO:1. The polypeptide provided by the invention has small molecular weight, is easy to synthesize, has low immunogenicity, has a good therapeutic effect on acute pancreatitis, can be used as a new type of medicine for acute pancreatitis, and has broad application prospects.